{"id":552900,"date":"2026-01-30T02:14:19","date_gmt":"2026-01-30T02:14:19","guid":{"rendered":"https:\/\/www.europesays.com\/us\/552900\/"},"modified":"2026-01-30T02:14:19","modified_gmt":"2026-01-30T02:14:19","slug":"expert-guide-to-all-the-types-of-glp-1-drugs-available-in-2026","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/552900\/","title":{"rendered":"Expert guide to all the types of GLP-1 drugs available in 2026"},"content":{"rendered":"

Ozempic has become so embedded in global culture that \u201cOzempic face\u201d<\/a> was shortlisted for a prominent dictionary\u2019s word of the year<\/a> in 2025.<\/p>\n

Ozempic<\/a> isn\u2019t the only drug that mimics the natural GLP-1 hormone, so users feel fuller for longer and eat less. There\u2019s also Zepbound<\/a>, Mounjaro, Trulicity and Victoza \u2014 and many more on the horizon for people with obesity or Type 2 diabetes.<\/p>\n

\"A<\/a>GLP-1 drugs have been around for more than 20 years, and the options are constantly evolving. lavju83 \u2013 stock.adobe.com<\/p>\n

GLP-1 meds stimulate insulin production when blood sugar is high, stop the liver from releasing excess sugar and slow stomach emptying to prevent blood sugar spikes after meals.<\/p>\n

With more GLP-1 options than ever before, choosing the right one can be difficult. Some are shots, others are pills, some need to be taken daily, others weekly.<\/p>\n

Here\u2019s a look at what\u2019s on the market \u2014 and what\u2019s potentially in the pipeline for 2026.<\/p>\n

Though other GLP-1s have been around longer, Novo Nordisk\u2019s Ozempic is probably the most widely known.<\/p>\n

The Food and Drug Administration approved Ozempic in 2017 for adults with Type 2 diabetes. Wegovy<\/a> was approved to treat obesity in 2021.<\/p>\n

They are both once-weekly injections, but Wegovy uses a higher maintenance dose of semaglutide than Ozempic. In December 2025, the FDA approved a once-daily pill version of Wegovy<\/a>.<\/p>\n

\"Close-up<\/a>Ozempic is the most widely known GLP-1. It\u2019s prescribed to people with Type 2 diabetes. martenaba \u2013 stock.adobe.com<\/p>\n

There was already a semaglutide pill on the market. Rybelsus was approved in 2019 for Type 2 diabetes \u2014 the daily tablet was the first oral GLP-1.<\/p>\n

There isn\u2019t an official FDA-approved generic version of semaglutide.<\/p>\n

Common side effects<\/a> include nausea, vomiting, diarrhea, constipation, bloating, gas and stomach pain.<\/p>\n

Individuals with a history of medullary thyroid carcinoma (a rare neuroendocrine tumor known as MTC) or multiple endocrine neoplasia syndrome type 2 (a hereditary cancer known as MEN 2) should not take semaglutide due to an increased risk of thyroid C-cell tumors in rodents.<\/p>\n

Tirzepatide differs from other GLP-1s in that it mimics the GLP-1 and GIP hormones.<\/p>\n

GIP promotes fat storage and can be more effective than GLP-1 in certain ways.<\/p>\n

The FDA approved Lilly\u2019s Mounjaro for Type 2 diabetes in 2022 and Zepbound for obesity in 2023. They are once-weekly injections that share identical dosing schedules and strengths.<\/p>\n

New York Post may receive revenue from affiliate and advertising partnerships for sharing this content and\/or when you make a purchase.<\/p>\n

There is no FDA-approved generic version of tirzepatide.<\/p>\n

Common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion and heartburn\/acid reflux.<\/p>\n

Avoid use if you have a personal or family history of MTC or MEN 2.<\/p>\n

The FDA approved Novo Nordisk\u2019s Victoza for Type 2 diabetes in 2010 and Saxenda for obesity in 2014.<\/p>\n

Both are daily injections \u2014 the main difference is the dosage. Saxenda has a higher maximum dosage of liraglutide than Victoza.<\/p>\n

Generic Victoza was approved in 2024 and generic Saxenda the following year.<\/p>\n

Common side effects include nausea, diarrhea, constipation, vomiting and indigestion.<\/p>\n

Avoid taking liraglutide if you have a personal or family history of MTC or MEN 2, as these drugs carry a boxed warning<\/a> for thyroid C-cell tumors.<\/p>\n

Dulaglutide<\/p>\n

Eli Lilly\u2019s Trulicity is the only available version of dulaglutide.<\/p>\n

The FDA approved Trulicity in 2014 to treat Type 2 diabetes in conjunction with diet and exercise. The weekly injection is not approved for weight loss.<\/p>\n

\"TwoEli Lilly\u2019s Trulicity, the only available version of dulaglutide, has been on the market for over a decade. Claudio Caridi \u2013 stock.adobe.com<\/p>\n

Common side effects include nausea, diarrhea and stomach pain.<\/p>\n

Trulicity also carries a boxed warning<\/a> that it can potentially cause thyroid C-cell tumors in rats, though it\u2019s unknown if this risk translates to humans. That\u2019s why people who have had MTC or MEN 2 should avoid use.<\/p>\n

Exenatide<\/p>\n

The FDA OK\u2019d exenatide in 2005, making it the first approved GLP-1 for Type 2 diabetes.<\/p>\n

It came in several forms \u2014 Byetta\u2019s a twice-daily injection, Bydureon a once-weekly jab, and Bydureon BCise a weekly dose administered with an autoinjector pen.<\/p>\n

\"ByettaByetta was the first GLP-1 approved by the FDA. It was OK\u2019d in 2005 for Type 2 diabetes. VIA BLOOMBERG NEWS<\/p>\n

AstraZeneca discontinued these three formulations in the US in recent years, but generic Byetta was approved by the FDA in late 2024.<\/p>\n

Common side effects of the drug include nausea, vomiting, diarrhea, constipation and indigestion.<\/p>\n

People should not take exenatide if they have severe kidney disease, significantly slowed digestion or diabetic ketoacidosis.<\/p>\n

Lixisenatide<\/p>\n

The FDA approved lixisenatide, marketed as Adlyxin, in 2016 for Type 2 diabetes.<\/p>\n

The daily pen injection is often combined with insulin.<\/p>\n

Adlyxin was discontinued in the US as of 2023, but lixisenatide can be found in Europe and other markets under the brand name Lyxumia. Lixisenatide is also a key ingredient in the diabetes drug Soliqua, which is available in the US.<\/p>\n

Common side effects include nausea, vomiting, diarrhea, constipation and abdominal pain, as well as\u00a0headache and dizziness.<\/p>\n

Watch for these drugs in 2026<\/p>\n

Lilly\u2019s orforglipron<\/a> differs from other GLP-1 drugs in that it\u2019s not a peptide that breaks down in stomach acid.<\/p>\n

Its small molecule structure allows it to pass through the stomach intact. The once-daily pill is anticipated to garner FDA approval for obesity and launch in the US in mid-to-late 2026.<\/p>\n

Lilly\u2019s retatrutide<\/a> has earned the nicknames \u201cGLP-3\u201d and \u201ctriple G\u201d because it mimics GLP-1, GIP and glucagon, which stimulate the liver to produce and release glucose.<\/p>\n

It\u2019s injected once weekly and is expected to be submitted to the FDA for approval in 2026.<\/p>\n

New York Post may receive revenue from affiliate and advertising partnerships for sharing this content and\/or when you make a purchase.<\/p>\n","protected":false},"excerpt":{"rendered":"Ozempic has become so embedded in global culture that \u201cOzempic face\u201d was shortlisted for a prominent dictionary\u2019s word…\n","protected":false},"author":3,"featured_media":552901,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[3655,151,210,22678,1184,10943,427,11825,67,132,68],"class_list":{"0":"post-552900","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health","8":"tag-diabetes","9":"tag-fda","10":"tag-health","11":"tag-hormones","12":"tag-medicine","13":"tag-obesity","14":"tag-ozempic","15":"tag-prescription-drugs","16":"tag-united-states","17":"tag-unitedstates","18":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115981639113190388","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/552900","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=552900"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/552900\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/552901"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=552900"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=552900"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=552900"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}